AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18313371
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg zopiclone (reference)
Trial: 15801925
Drug: Micafungin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (150 mg/day)
Trial: 15801925
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg/day)
Trial: 27128532
Drug: One-quarter standard-dose
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-quarter standard-dose ticagrelor
Trial: 30252571
Drug: Half standard-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half standard-dose ticagrelor
Trial: 30252571
Drug: Standard-dose ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose ticagrelor
Trial: 30252571
Drug: Ticagrelor groups
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor groups (all doses)
Trial: 30252571
Drug: Half and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half and standard-dose ticagrelor
Trial: 27762434
Drug: Oxycodone-naloxone
RxNorm normalized name: naloxone / oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone-naloxone
Trial: 16148323
Drug: Structured interview
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured interview (Schedule for Affective Disorders and Schizophrenia for School‐aged Children‐Present and Lifetime Versions) administered by a trained interviewer before the initial physician visit
Trial: 12133120
Drug: Alpha-2-adrenergic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-2-adrenergic agents and naltrexone (control group 2)
Trial: 9918565
Drug: Dextromethorphan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (50 mg DEM hydrobromide orally)
Trial: 9918565
Drug: Quinidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (50 mg Qd sulfate orally)
Trial: 2224916
Drug: Etretinate 25
RxNorm normalized name: etretinate 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate 25 mg daily
Trial: 26357943
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy-informed software application (Actissist) plus Treatment As Usual (TAU)
Trial: 26357943
Drug: Symptom monitoring
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom monitoring software application (ClinTouch) plus Treatment As Usual (TAU)
Trial: 21419704
Drug: AAV2‐GAD infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV2‐GAD infusions
Trial: 9771860
Drug: 6 IU
RxNorm normalized name: Coenzyme Q10/Vitamin E 30 MG-6 IU Oral Capsule, Liquid Filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 IU GH twice daily from 2 days before to 7 days after the operation
Trial: 7819101
Drug: Soluble interleukin‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble interleukin‐2 receptor (sIL‐2r)
Trial: 7819101
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of elevated IL‐10 and sIL‐2r > 3000 U/ml
Trial: 7819101
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IL‐10 with sIL‐2r
Trial: 3046294
Drug: intravenous anisoylated
RxNorm normalized name: Anisoylated plasminogen streptokinase activator complex
DrugBank: Anistreplase (DB00029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Trial: 24206873
Drug: DCB (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCB (3 μg/mm²) followed by CoCr-stent
Trial: 20847736
Drug: PDA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDA with self-monitoring software and daily feedback messages (PDA+FB)
Trial: 18082667
Drug: 600 mcg
RxNorm normalized name: Biotin 600 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mcg of vaginal misoprostol every 6 h up to four doses
Trial: 18082667
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg of vaginal misoprostol every 4 h up to five doses
Trial: 16678205
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg QD (after switching from placebo)
Trial: 11076429
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron plus i.v. dexamethasone
Trial: 11076429
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron plus i.v. dexamethasone
Trial: 9084348
Drug: Etidronate, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate, 800 mg orally, once per day for 2 weeks of 15 weeks, repeated once.
Trial: 9084348
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (without etidronate).
Trial: 8210923
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg etodolac SR once a day for up to 52 weeks
Trial: 8210923
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg etodolac SR once a day for up to 52 weeks
Trial: 3730528
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg innovator product
Trial: 3730528
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg generic product
Trial: 3730528
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg solution
Trial: 29757462
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g guava/day
Trial: 29757462
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg synthetic vitamin C/day
Trial: 27424313
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of n-3 FA 2 g + fenofibrate 160 mg
Trial: 20855072
Drug: Fenofibrate 160
RxNorm normalized name: fenofibrate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 160 mg
Trial: 27424313
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of n-3 FA + fenofibrate
Trial: 23428122
Drug: GABA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA treatment (25-30 mg/kg•d)
Trial: 23428122
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for asthma
Trial: 12670780
Drug: montelukast 10mg
RxNorm normalized name: montelukast 10 MG
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: montelukast 10mg daily
Trial: 12670780
Drug: budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide 400 microg twice a day (bid)
Trial: 12670780
Drug: montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: montelukast 10 mg daily plus budesonide 400 microg bid
Trial: 11910586
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol in 1 g gel daily + 10 mg medroxyprogesterone acetate for the first 12 days every month (Group I)
Trial: 11910586
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol in 1 g gel daily + 10 mg medroxyprogesterone acetate for the first 12 days every 3 months (Group II)
Trial: 11910586
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol in 1 g gel daily + 10 mg medroxyprogesterone acetate for the first 12 days every month (Group III)
Trial: 11910586
Drug: Acceptability of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptability of the gel
Trial: 1473437
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g 5‐ASA foam
Trial: 1473437
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g 5‐ASA enema
Trial: 6237836
Drug: Zimelidine (Z),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine (Z), 200 mg by mouth, preceded by 1 hr and followed for 7 hr of oral ethanol (E) in juice dosed to maintain blood alcohol concentrations between 800 and 1000 mg/l
Trial: 28138381
Drug: d-Cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: d-Cycloserine (DCS) 50 mg administered 30 min prior to group social skills training
Trial: 28138381
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 30 min prior to group social skills training
Trial: 27703725
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly extended release exenatide for 24 weeks
Trial: 24326981
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of vitamin E plus 400 mg of vitamin C
Trial: 17727580
Drug: Standard gravitational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard gravitational infusion sets without IV(2) flow
Trial: 15685462
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (saline injection)
Trial: 6282926
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (IGIV), 5%, in 10% maltose, administered at a dose of 20 cc/kg
Trial: 6282926
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (IGIV), 5%, in 10% maltose, at doses lower than 20 cc/kg
Trial: 6282926
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (IGIV) administered at 20 cc/kg once every week (currently under evaluation)
Trial: 6177709
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (IGIV)
Trial: 30666966
Drug: 2‐L low‐volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐L low‐volume bowel preparation regimen
Trial: 30666966
Drug: 4‐L high‐volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐L high‐volume bowel preparation regimen
Trial: 30666966
Drug: Low‐volume preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐volume preparation
Trial: 21153945
Drug: Daily interruption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interruption of sedative infusion (Group P, n=25)
Trial: 15786484
Drug: Pharmacotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy plus family intervention
Trial: 7797776
Drug: Insulin-glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-glucose infusion followed by multidose subcutaneous insulin for > or = 3 months
Trial: 23611569
Drug: Vilazodone 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilazodone 10, 20, 40, 60, and 80 mg/day
Trial: 17660177
Drug: Remifentanil 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.1 microg/kg combined with propofol 1 mg/kg
Trial: 17660177
Drug: Remifentanil 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.1 microg/kg combined with midazolam 0.05 mg/kg
Trial: 11833836
Drug: Clinafloxacin 200
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clinafloxacin 200 mg IV every 12 hours
Trial: 11833836
Drug: Piperacillin/tazobactam 3.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 3.375 g IV every 6 hours
Trial: 10511931
Drug: AK incisions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK incisions with collagen implants
Trial: 10511931
Drug: AK incisions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK incisions without collagen implants (Control)
Trial: 7856671
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (10 L/min by face mask)
Trial: 7856671
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy for ≤ 10 minutes
Trial: 7856671
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy for > 10 minutes
Trial: 20116706
Drug: Single-dose antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose antibiotic prophylaxis
Trial: 2686291
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without antibiotic prophylaxis
Trial: 7042092
Drug: IF radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IF radiotherapy plus MOPP chemotherapy
Trial: 30554882
Drug: BNO 1030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNO 1030 (Imupret®) as a supplement to standard symptomatic therapy
Trial: 26575144
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 μg/kg bolus followed by 0.2 to 0.7 μg/kg/h infusion)
Trial: 26575144
Drug: Propofol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (25 to 50 μg/kg/min infusion)
Trial: 25123162
Drug: Multiple courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple courses of antenatal corticosteroids (ACS) therapy
Trial: 25123162
Drug: Single course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single course of antenatal corticosteroids (ACS) therapy
Trial: 22757662
Drug: Sodium picosulphate
RxNorm normalized name: Sodium Picosulfate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium picosulphate (Picoprep) bowel preparation
Trial: 19201016
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of desloratadine
Trial: 19201016
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of desloratadine
Trial: 12164403
Drug: Phlogenzym (bromelain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlogenzym (bromelain 90 mg, trypsin 48 mg, rutin 100 mg)
Trial: 7812574
Drug: salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol (50 micrograms twice daily)
Trial: 1972797
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms dexmedetomidine (MPV‐1440), a selective alpha 2‐adrenoceptor agonist
Trial: 1972797
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg atipamezole (MPV‐1248), a selective alpha 2‐adrenoceptor antagonist
Trial: 31475470
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with non‐ablative fractional laser and intralesional steroid injection (1550‐nm erbium‐glass fractional laser treatment)
Trial: 31475470
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with non‐ablative fractional laser and intralesional steroid injection
Trial: 31475470
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (steroid injection alone)
Trial: 27303788
Drug: S-1 (≥77.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (≥77.6 mg/m2/day)
Trial: 27303788
Drug: S-1 (≤65.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (≤65.9 mg/m2/day)
Trial: 27303788
Drug: GS (≥65.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS (≥65.1 mg/m2/day)
Trial: 27303788
Drug: GS (≤53.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS (≤53.8 mg/m2/day)
Trial: 23118932
Drug: GTP (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTP (500 mg daily)
Trial: 23118932
Drug: GTP (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTP (500 mg daily) + TC (60-minute group exercise, 3 times/week)
Trial: 21048953
Drug: Recombinant replication-defective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant replication-defective adenovirus type 5 (rAd5) vaccine expressing HIV-1 Gag, Pol, and multiclade Env proteins, VRC-HIVADV014-00-VP, at a dose of 10^10 or 10^11 adenovector particle units
Trial: 21048953
Drug: Recombinant replication-defective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant replication-defective adenovirus type 5 (rAd5) vaccine
Trial: 15969949
Drug: Rapidly disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapidly disintegrating stanol lecithin tablets (1.26 g stanols daily)
Trial: 15969949
Drug: Slowly disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slowly disintegrating capsules (1.01 g daily)
Trial: 12324640
Drug: Polynutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polynutrient supplement (twice daily for 10 weeks)
Trial: 12324640
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 10 weeks)
Trial: 8643170
Drug: High-dose iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose iron therapy (100 mg at the end of HD treatment)
Trial: 8643170
Drug: Low-dose iron
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose iron therapy (10, 20, or 40 mg per HD depending on haemoglobin, serum ferritin, and transferrin saturation)
Trial: 8643170
Drug: Intravenous rHuEpo
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rHuEpo therapy
Trial: 8643170
Drug: Subcutaneous rHuEpo
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous rHuEpo therapy
Trial: 8643170
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of iron administration
Trial: 8643170
Drug: rHuEpo therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo therapy in well-nourished patients (serum albumin > 40 g/l) without hyperparathyroidism
Trial: 8643170
Drug: rHuEpo therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo therapy in patients with hyperparathyroidism
Trial: 336178
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy (control)
Trial: 27406639
Drug: Antenatal integrative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antenatal integrative medicine education programme plus standard care
Trial: 22143925
Drug: Intraarticular injection
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injection of gadopentetate dimeglumine, ropivacaine 0.5%, and normal saline (group A)
Trial: 22143925
Drug: Intraarticular injection
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injection of gadopentetate dimeglumine and normal saline (group B)
Trial: 31777761
Drug: Asoprisnil 25
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asoprisnil 25 mg
Trial: 14652471
Drug: Fear-avoidance-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fear-avoidance-based physical therapy (n = 34)
Trial: 14652471
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care physical therapy (n = 32)
Trial: 8866803
Drug: Five-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-valent pneumococcal conjugate vaccine (3 doses of 5 micrograms of types 6B, 14, 18, 19F, and 23F polysaccharides conjugated to CRM197)
Trial: 8866803
Drug: H. influenzae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. influenzae type b vaccine (2 doses)
Trial: 1632567
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 to 50 mg three times a day)
Trial: 1632567
Drug: Nadolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (20 to 160 mg once a day)
Trial: 6436700
Drug: Leuprolide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide (1 mg subcutaneously daily)
Trial: 6436700
Drug: Diethylstilbestrol (DES,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (DES, 3 mg by mouth daily)
Trial: 20083693
Drug: pimecrolimus, 1%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pimecrolimus, 1%, cream